Published in Br J Clin Pharmacol on March 01, 1993
Safety evaluation of fixed combination piperaquine plus dihydroartemisinin (Artekin) in Cambodian children and adults with malaria. Br J Clin Pharmacol (2004) 1.84
Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol (2003) 1.55
Pharmacokinetic-pharmacodynamic modeling in the data analysis and interpretation of drug-induced QT/QTc prolongation. AAPS J (2005) 1.37
Stereoselective Inhibition of the hERG1 Potassium Channel. Front Pharmacol (2010) 0.83
Cardiac complications of unwitting co-injection of quinine/quinidine with heroin in an intravenous drug user. J Gen Intern Med (2012) 0.77
Interspecies allometric scaling of antimalarial drugs and potential application to pediatric dosing. Antimicrob Agents Chemother (2014) 0.75
The pharmacokinetics and pharmacodynamics of quinine in the diabetic and non-diabetic elderly. Br J Clin Pharmacol (1994) 0.75
Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm (1978) 10.01
Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther (1979) 5.13
QUANTITATIVE DETERMINATION OF QUINIDINE IN PLASMA. Scand J Clin Lab Invest (1963) 3.95
Quinine pharmacokinetics and toxicity in cerebral and uncomplicated Falciparum malaria. Am J Med (1982) 2.71
Intravenous quinidine for the treatment of severe falciparum malaria. Clinical and pharmacokinetic studies. N Engl J Med (1985) 2.12
Treatment of severe malaria in the United States with a continuous infusion of quinidine gluconate and exchange transfusion. N Engl J Med (1989) 1.88
Concept of a volume of distribution and possible errors in evaluation of this parameter. J Pharm Sci (1968) 1.82
Binding of quinine to plasma proteins in falciparum malaria. Am J Trop Med Hyg (1985) 1.73
Quinidine in falciparum malaria. Lancet (1981) 1.65
Clinical pharmacokinetics of quinidine. Clin Pharmacokinet (1980) 1.59
Quinine disposition kinetics. Br J Clin Pharmacol (1983) 1.41
Alpha 1-acid glycoprotein (orosomucoid) and plasma protein binding of quinine in falciparum malaria. Br J Clin Pharmacol (1991) 1.23
The effect of quinidine and its metabolites on the electrocardiogram and systolic time intervals: concentration--effect relationships. Br J Clin Pharmacol (1981) 1.19
The pharmacokinetics of quinine and quinidine in malaria. Acta Leiden (1987) 1.14
STUDIES ON THE CHEMOTHERAPY OF THE HUMAN MALARIAS. III. THE PHYSIOLOGICAL DISPOSITION AND ANTIMALARIAL ACTIVITY OF THE CINCHONA ALKALOIDS. J Clin Invest (1948) 1.13
Determination of quinine and quinidine in biological fluids by high performance liquid chromatography. Southeast Asian J Trop Med Public Health (1989) 1.08
Differences in the binding of quinine and quinidine to plasma proteins. Br J Clin Pharmacol (1987) 1.08
A safe and effective consecutive-infusion regimen for rapid quinine loading in severe falciparum malaria. J Infect Dis (1990) 1.03
Pharmacokinetic studies of quinidine in patients with arrhythmias. Circulation (1977) 1.02
Quinidine pharmacokinetics in man: choice of a disposition model and absolute bioavailability studies. J Pharmacokinet Biopharm (1979) 0.98
Quinine pharmacokinetics in cerebral malaria: predicted plasma concentrations after rapid intravenous loading using a two-compartment model. Trans R Soc Trop Med Hyg (1988) 0.95
Single-dose comparative kinetics and bioavailability study of quinine hydrochloride, quinidine sulfate and quinidine bisulfate sustained-release in healthy male volunteers. Acta Leiden (1988) 0.90
In vivo and in vitro responses to quinine and quinidine of Plasmodium falciparum. Bull World Health Organ (1988) 0.85
Safety and efficacy of intravenous quinidine. Am J Med (1983) 0.83
Quinine induces reversible high-tone hearing loss. Br J Clin Pharmacol (1990) 0.80
Slow-release quinidine in the treatment of chloroquine resistant falciparum malaria: a double-blind trial. Acta Leiden (1987) 0.78
Averting a malaria disaster. Lancet (1999) 9.40
Melioidosis: a major cause of community-acquired septicemia in northeastern Thailand. J Infect Dis (1989) 8.24
Effects of artemisinin derivatives on malaria transmissibility. Lancet (1996) 7.42
Human cerebral malaria. A quantitative ultrastructural analysis of parasitized erythrocyte sequestration. Am J Pathol (1985) 7.14
Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet (2000) 7.06
Dexamethasone proves deleterious in cerebral malaria. A double-blind trial in 100 comatose patients. N Engl J Med (1982) 6.73
Neurological manifestations of dengue infection. Lancet (2000) 5.69
The epidemiology of malaria in a Karen population on the western border of Thailand. Trans R Soc Trop Med Hyg (1996) 5.35
An immunohistochemical study of the pathology of fatal malaria. Evidence for widespread endothelial activation and a potential role for intercellular adhesion molecule-1 in cerebral sequestration. Am J Pathol (1994) 5.34
Qinghaosu. Lancet (1993) 5.25
Halofantrine versus mefloquine in treatment of multidrug-resistant falciparum malaria. Lancet (1993) 5.11
Plasmodium falciparum: in vitro studies of the pharmacodynamic properties of drugs used for the treatment of severe malaria. Exp Parasitol (1993) 4.98
Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Shoklo SPf66 Malaria Vaccine Trial Group. Lancet (1996) 4.90
Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob Agents Chemother (2000) 4.77
A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria. N Engl J Med (1996) 4.64
The pfmdr1 gene is associated with a multidrug-resistant phenotype in Plasmodium falciparum from the western border of Thailand. Antimicrob Agents Chemother (1999) 4.64
Plasmodium falciparum antimalarial drug susceptibility on the north-western border of Thailand during five years of extensive use of artesunate-mefloquine. Trans R Soc Trop Med Hyg (2000) 4.63
Application of genetic markers to the identification of recrudescent Plasmodium falciparum infections on the northwestern border of Thailand. Am J Trop Med Hyg (1999) 4.60
Quinolone-resistant Salmonella typhi in Viet Nam: molecular basis of resistance and clinical response to treatment. Clin Infect Dis (1997) 4.53
The epidemiology of severe malaria in an area of low transmission in Thailand. Trans R Soc Trop Med Hyg (1997) 4.48
Pre-referral rectal artesunate to prevent death and disability in severe malaria: a placebo-controlled trial. Lancet (2008) 4.35
Fake antimalarials in Southeast Asia are a major impediment to malaria control: multinational cross-sectional survey on the prevalence of fake antimalarials. Trop Med Int Health (2004) 4.35
Treatment of multidrug-resistant Plasmodium falciparum malaria with 3-day artesunate-mefloquine combination. J Infect Dis (1994) 4.17
Fake artesunate in southeast Asia. Lancet (2001) 3.84
Mefloquine-resistant falciparum malaria on the Thai-Burmese border. Lancet (1991) 3.72
A quantitative analysis of the microvascular sequestration of malaria parasites in the human brain. Am J Pathol (1999) 3.72
Diagnosis of adult tuberculous meningitis by use of clinical and laboratory features. Lancet (2002) 3.65
Effects of Plasmodium vivax malaria in pregnancy. Lancet (1999) 3.62
Identification of Pseudomonas pseudomallei in clinical practice: use of simple screening tests and API 20NE. J Clin Pathol (1989) 3.57
Therapeutic responses to different antimalarial drugs in vivax malaria. Antimicrob Agents Chemother (2000) 3.46
Factors contributing to anemia after uncomplicated falciparum malaria. Am J Trop Med Hyg (2001) 3.46
Artesunate/mefloquine treatment of multi-drug resistant falciparum malaria. Trans R Soc Trop Med Hyg (1998) 3.39
Persistence of Plasmodium falciparum HRP-2 in successfully treated acute falciparum malaria. Trans R Soc Trop Med Hyg (2001) 3.32
Cardiac effects of antimalarial treatment with halofantrine. Lancet (1993) 3.32
A phase II clinical trial of mefloquine in patients with chloroquine-resistant falciparum malaria in Thailand. Bull World Health Organ (1983) 3.31
The epidemiology of melioidosis in Ubon Ratchatani, northeast Thailand. Int J Epidemiol (1994) 3.23
Neurological sequelae of cerebral malaria in children. Lancet (1990) 3.11
Malaria during pregnancy in an area of unstable endemicity. Trans R Soc Trop Med Hyg (1992) 3.10
Severe hypoglycemia and hyperinsulinemia in falciparum malaria. N Engl J Med (1983) 3.07
Clinical pharmacokinetics of antimalarial drugs. Clin Pharmacokinet (1985) 3.03
A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand. Am J Trop Med Hyg (2001) 3.03
Quantitation of bacteria in blood of typhoid fever patients and relationship between counts and clinical features, transmissibility, and antibiotic resistance. J Clin Microbiol (1998) 3.02
Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria. Am J Trop Med Hyg (1999) 2.98
Risk factors for gametocyte carriage in uncomplicated falciparum malaria. Am J Trop Med Hyg (1999) 2.94
Relation of the stage of parasite development in the peripheral blood to prognosis in severe falciparum malaria. Trans R Soc Trop Med Hyg (1993) 2.90
Molecular basis of sequestration in severe and uncomplicated Plasmodium falciparum malaria: differential adhesion of infected erythrocytes to CD36 and ICAM-1. J Infect Dis (1991) 2.87
Direct in vivo assessment of microcirculatory dysfunction in severe falciparum malaria. J Infect Dis (2008) 2.77
Artemether-lumefantrine for the treatment of multidrug-resistant falciparum malaria. Trans R Soc Trop Med Hyg (2000) 2.76
Arabinose assimilation defines a nonvirulent biotype of Burkholderia pseudomallei. Infect Immun (1997) 2.72
Quinine pharmacokinetics and toxicity in cerebral and uncomplicated Falciparum malaria. Am J Med (1982) 2.71
Population dynamics of untreated Plasmodium falciparum malaria within the adult human host during the expansion phase of the infection. Parasitology (2002) 2.67
Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based study. Lancet Infect Dis (2011) 2.65
Randomized comparison of artemether-benflumetol and artesunate-mefloquine in treatment of multidrug-resistant falciparum malaria. Antimicrob Agents Chemother (1998) 2.61
Relapse in melioidosis: incidence and risk factors. J Infect Dis (1993) 2.61
Antimalarial drugs reduce cytoadherence and rosetting Plasmodium falciparum. J Infect Dis (1996) 2.59
Clinical features cannot predict a diagnosis of malaria or differentiate the infecting species in children living in an area of low transmission. Trans R Soc Trop Med Hyg (1998) 2.54
Quantitative recovery of Burkholderia pseudomallei from soil in Thailand. Trans R Soc Trop Med Hyg (1996) 2.54
Mefloquine pharmacokinetic-pharmacodynamic models: implications for dosing and resistance. Antimicrob Agents Chemother (2000) 2.54
Quantitation of bacteria in bone marrow from patients with typhoid fever: relationship between counts and clinical features. J Clin Microbiol (2001) 2.53
High rate of Plasmodium vivax relapse following treatment of falciparum malaria in Thailand. Lancet (1987) 2.52
The prognostic and pathophysiologic role of pro- and antiinflammatory cytokines in severe malaria. J Infect Dis (1999) 2.49
The antimicrobial susceptibility of Pseudomonas pseudomallei. Emergence of resistance in vitro and during treatment. J Antimicrob Chemother (1989) 2.44
Microsatellite variation, repeat array length, and population history of Plasmodium vivax. Mol Biol Evol (2006) 2.43
The pathophysiologic and prognostic significance of acidosis in severe adult malaria. Crit Care Med (2000) 2.42
The effects of dopamine and adrenaline infusions on acid-base balance and systemic haemodynamics in severe infection. Lancet (1996) 2.41
Poliomyelitis-like illness due to Japanese encephalitis virus. Lancet (1998) 2.41
Association of genetic mutations in Plasmodium vivax dhfr with resistance to sulfadoxine-pyrimethamine: geographical and clinical correlates. Antimicrob Agents Chemother (2001) 2.40
The use of selective media for the isolation of Pseudomonas pseudomallei in clinical practice. J Med Microbiol (1990) 2.39
Bacteriological studies of the venom and mouth cavities of wild Malayan pit vipers (Calloselasma rhodostoma) in southern Thailand. Trans R Soc Trop Med Hyg (1991) 2.38
The mechanisms of parasite clearance after antimalarial treatment of Plasmodium falciparum malaria. J Infect Dis (2000) 2.35
Semi-quantitative measurement of Plasmodium falciparum antigen PfHRP2 in blood and plasma. Trans R Soc Trop Med Hyg (1997) 2.33
Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. Clin Pharmacokinet (1996) 2.33
Pharmacokinetic determinants of the window of selection for antimalarial drug resistance. Antimicrob Agents Chemother (2008) 2.27
Predictors of mefloquine treatment failure: a prospective study of 1590 patients with uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg (1996) 2.24
Mefloquine prophylaxis prevents malaria during pregnancy: a double-blind, placebo-controlled study. J Infect Dis (1994) 2.23
Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand. Antimicrob Agents Chemother (2008) 2.23
Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives. Am J Trop Med Hyg (1999) 2.23